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Recent studies have implicated nitric oxide and peroxynitrite in the pathogenesis of many
diseases, such as septic shock, arthritis, lung disease, and atherosclerosis. Nitric oxide ('NO)
exerts many diverse effects on vascular tone, affecting neurotransmission and cellular
cytotoxicity/communication. Our laboratory and others have documented a proinflammatory role
for 'NO in ocular inflammation. Uveitis, which is an inflammation of the highly vascular uveal tract
in the eye, is a debilitating condition that can lead to visual impairment and blindness. It is
characterized by acute, recurrent, or persistent inflammation with disruption of the
blood-aqueous barrier and is accompanied by protein leakage and leukocyte infiltration into the
aqueous humor and anterior chamber. Systemic injection of endotoxin into mice and rats, or
intraocular injection of endotoxin into mice, rats, and rabbits induces acute uveitis, which clinically
and histologically resembles acute anterior uveitis in humans. These models facilitate the study of
pathogenic mechanisms that contribute to ocular inflammation. In addition to 'NO, superoxide
anion radicals (02'-), and peroxynitrite (ONOO-), the products of the reaction between 'NO and
02'-, are also implicated in uveitis. The role of peroxynitrite in ocular inflammation is still largely
unknown. Characterization of the roles of these important uveitic mediators in the ocular
inflammatory response will provide information critical to the understanding of the pathogenesis
of intraocular inflammation so that more effective therapeutic intervention(s) can be developed.
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Introduction
Intense research has focused on the role of
nitric oxide ('NO) and peroxynitrite
(ONOO-) in physiologic and pathophysio-
logic processes. *NO is beneficial and nec-
essary for normal physiologic processes such
as vasodilation (1), platelet functions (2),
and neurotransmission (3.4). In contrast,
higher concentrations of 'NO are thought
to be cytotoxic and may contribute to cell
injury or inflammation in many disease
states such as arthritis (5), lung disease (6),
and atherosclerosis (7). The detrimental
toxic effects of 'NO may be due to the
formation of ONOO- from the reaction
between 'NO and superoxide anion radical
(02--). Recent studies suggest that
ONOO- may also have both beneficial and
detrimental effects (8).
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The role of NO in the eye has been
extensively investigated. The contribution of
this regulatory molecule to ocular physiol-
ogy is emerging, but additional attention
must be directed toward the understanding
of the pathology ofeye diseases. To this
end, animal models ofuveitis have been
extensively used to try to elucidate the com-
plex cascade ofevents leading to uveitis.
Uveitis involves the recruitment ofleuko-
cytes into the uvea and the disruption ofthe
blood barrier, resulting in protein extravasa-
tion and cellular infiltration into the aque-
ous humor and anterior chamber (9,10).
Studies from animal models ofuveitis and
human patients with uveitis implicate reac-
tive oxygen/nitrogen radicals in this inflam-
matory process. In the studies detailed
below, the importance ofthe reactive radi-
cals in the initiation and development of
ocular inflammationwill be discussed.
Nitric Oxide
Nitric oxide is a small, membrane-permeable
free radical synthesized from the terminal
guanidino nitrogen of L-arginine by the
enzyme 'NO synthase (NOS) (11). NOS
exists in three isoforms and is differ-
entially expressed in many different cell
types (12,13). The different isoforms are
transcribed from three distinct genes and
catalyze the oxidation of L-arginine to
L-citrulline (14,15). Required cofactors
include NADPH, flavin adenine dinu-
cleotide, flavin mononucleotide, calmod-
ulin, heme, and tetrahydrobiopterin. The
three NOS isoforms differ in calcium
dependence, tissue distribution, amino
acid sequence, regulation of expression,
and function (16).
Endothelial NOS (eNOS or NOS3;
135 kDa) and neuronal NOS (nNOS or
NOSI; 150-160 kDa) are constitutively
expressed, require calcium, and are collec-
tively referred to as constitutive NOS
(cNOS) (3,17,18). Small amounts of NO
are produced by these enzymes. 'NO gen-
erated from the eNOS pathway activates
soluble guanylyl cyclase to produce the
intracellular signaling molecule cGMP,
which functions to relax vascular smooth
muscle cells by decreasing intracellular cal-
cium (18,19). 'NO produced by nNOS
functions as a neurotransmitter in the
nervous system (3,4).
A third isoform, an inducible NOS
(iNOS or NOS2; 130 kDa), usually does
not exist under normal conditions and is
expressed in response to certain cytokines
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(interleukin [IL]-1I, tumor necrosis factor
[TNF]-a) and bacterial products (lipo-
polysaccharide [LPS]) (13,20,21). Many
cell types have the capacity to express
iNOS after exposure to certain immuno-
logic or inflammatory stimuli (22-29).
High concentrations of NO generated by
this pathway are sustained for prolonged
periods of time in vitro and in vivo
(13,30). iNOS expression is delayed 2 to
8 hr after exposure to inducing cytokines;
the delay is necessitated by the synthesis of
essential cofactors (31). Elevated levels of
NO generated by the iNOS are thought
to be involved in many inflammatory
conditions (32-35).
The production of NO can be inhib-
ited by analogs ofL-arginine, which com-
pete with L-arginine for the active site of
NOS (12,36-38). Nonamino acid com-
pounds also inhibit NOS activity (39).
Furthermore, inhibition of NO can be
achieved by limiting necessary cofactors of
NOS activity and inhibiting signal transduc-
tion and transcription ofNOS (39). NOS
inhibitors exhibit different specificities for
the NOS isoforms (22,39). For example,
aminoguanidine (AG) is a more selective
iNOS inhibitor (40,41) and NG-
monomethyl-L-arginine and N--nitro-L-argi-
nine methyl ester (L-NAME) inhibit both
cNOS and iNOS (22). More selective NOS
inhibitors are needed to dissect the involve-
ment ofthe different NOS isoforms in both
physiologic andpathophysiologic processes.
Peroxynitrite
Peroxynitrite is a potent oxidant that is
generated from NO and 02-- (42). Under
pathologic conditions such as ischemia-
reperfusion injury, inflammation, and sep-
sis, elevated levels of both NO and 02-
are produced by tissues. Because 02-
reacts with NO at a faster rate than with
superoxide dismutase (SOD), a scavenger
ofO2 -, ONOO- may be formed at high
yields and contribute to the pathology.
ONOO- is also implicated in the patho-
genesis ofrheumatoid arthritis, shock asso-
ciated with endotoxemia, silica-induced
lung injury, neurotoxicity, endothelial
injury, and colonic inflammation (43-45).
ONOO- directly and rapidly oxidizes
sulfhydryl groups and initiates lipid peroxi-
dation (46). Alternatively, ONOO- can
nitrate phenolic rings oftyrosine residues
ofproteins, leading to the formation of
nitrotyrosine, which is easily detected with
antinitrotyrosine antibodies (47). Thus,
the presence ofnitrotyrosine can serve as a
ONOO-"footprint."
Just as is the case for 'NO, other
studies suggest that ONOO- can mediate
physiologic processes that are beneficial.
ONOO- produces vascular relaxation in
isolated coronary (48) and pulmonary
arteries (49). It also inhibits platelet
aggregation (50). An important study by
Lefer et al. (8) provides evidence that
ONOO-, at nanomolar concentrations,
significantly inhibits leukocyte-endothelial
interactions both in vitro and in vivo by
inhibiting the upregulation ofP-selectin. In
addition, the study showed that polymor-
phonuclear accumulation in ischemic-
reperfused rat hearts was reduced by
nanomolar concentrations of ONOO-.
The differences in beneficial versus detri-
mental effects ofONOO- may be, at least
in part, concentration dependent, and
underscore the complex biochemistry of
'NO and ONOO-.
NO and ONOO- in the Eye
The function of NO in the eye has been
extensively studied, from physiologic and
pathophysiologic functions to therapeutic
potential (51). All three NOS isoforms
have been identified in different parts of
the eye, either with NADPH-diaphorase
staining or specific anti-NOS antibodies.
There are multiple sites of action for the
signaling properties of NO produced by
NOS1 and 3 isoforms. These NOS iso-
forms have been detected in the retina
and in vascular endothelium of the ante-
rior segment and choroid, in conjunctiva,
and in ciliary muscle and trabecular
meshwork. This suggests a therapeutic
potential for the use of NO donors
(nitrovasodilators) in controlling retinal
blood flow, aqueous humor dynamics,
and regulation of intraocular pressure.
Behar-Cohen et al. (52) evaluated the
effect of intraocular administration of
'NO donors in the rabbit eye and
observed a drastic decrease in intraocular
pressure, with no inflammatory or toxic
effects on ocular tissues. The NOS2 iso-
form produces larger amounts of NO,
which contributes to cytotoxicity, and has
been identified in the retina (pigmented
epithelium, pericytes, and Muller cells)
and iris-ciliary body. During uveitis,
infiltrating polymorphonuclear and
mononuclear cells express NOS2, proba-
bly after stimulation by uveitic cytokines
such as IL-1P and TNF-a.
In an experimental guinea pig model of
allergic conjunctivitis, 'NO was shown to
mediate increased conjunctival blood flow
and hyperpermeability ofsensitized guinea
pigs after exposure to the antigen (48 of
80), or to histamine. Increased levels of
nitrite were detected in lavage fluid 30 min
after challenge, along with conjunctivitis,
edema formation, and hyperpermeability.
These inflammatory parameters were
inhibited with pretreatment with L-NAME
or AG (53,54). Neurotoxicity of NO in
the retina was investigated in rabbits by
intravitreal injection of the 'NO donor
S-nitroso-N-acetylpenicillamine (55).
Retinal toxicity of 'NO was shown both
functionally and histologically, suggesting
that 'NO may play a role in retinal
ischemia or in degenerative diseases. As in
other physiologic and pathologic situa-
tions, the protective and detrimental
effects of NO and ONOO- are complex
and require further investigation. The abil-
ity of NO and ONOO- to lower intraoc-
ular pressure and increase retinal blood
flow suggests a beneficial use in treatment
of certain ocular situations such as glau-
coma, but the potential retinal toxicity
associated with increased 'NO should be
considered and investigated further.
NO and ONOO- in
Experimental Uveitis
In an experimental autoimmune uveitis
model, Wu et al. (56) demonstrated
ONOO- formation in the photoreceptors,
and to a lesser extent in the ganglion
cell layers, nerve fiber cell layers, and
blood vessels of the retina. These sites of
ONOO- production appear to correlate
with the area ofpathologic oxidation and
may be a major factor in the degeneration
ofphotoreceptors in this model.
Several investigations using the
endotoxin-induced uveitis (EIU) mouse
and rat models document the importance
of NO in ocular inflammation (57-65).
Intraperitoneal injections ofL-NAME, an
inhibitor ofboth cNOS and iNOS, signifi-
cantly decrease aqueous protein and cell
numbers in the anterior chamber ofEIU in
rats (60). Tilton et al. (59) used the more
specific iNOS inhibitor AG and demon-
strated that the hemodynamic and vascular
changes associated with EIU are in part
due to increased 'NO production. Others
have shown increased iNOS mRNA in the
iris-ciliary body in EIU by reverse tran-
scriptase-polymerase chain reaction (64)
and in situ hybridization (66). These
studies conclude that 'NO is an important
mediator of uveitis and that inhibition of
NOS decreases ocular inflammation.
The EIU model in rabbits is clinically
and histopathologically similar to acute
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anterior uveitis in humans (9,10). The
acute inflammation is associated with
vascular and permeability changes in the
anterior chamber ofthe eye. Studies ofthe
pathogenesis ofuveitis from human uveitis
and animal models ofocular inflammation
have identified increased cytokine (IL-15,
TNF-a, and IL-6) levels in uveitic ocular
fluids and tissues compared to normal flu-
ids and tissues (67-69). In addition,
prostaglandins and other mediators have
been associated with uveitis. Studies using
the EIU model in rabbits have documented
a role for NO and ONOO- in ocular
inflammation (65,70).
Endotoxin-induced uveitis in rabbits is
induced by a single intravitreal injection of
endotoxin (10 ng; Escherichia colt) into one
eye of New Zealand white male rabbits
(2-3 kg) and the appropriate vehicle into
the contralateral eye (9,10). Temporal
assessment ofuveitis is monitored by direct
examination ofthe anterior segment with a
slit-lamp biomicroscope. Evidence ofdis-
ruption ofocular barriers (protein extra-
vasation; "aqueous flare") is graded from 0
to 4, with 0 being normal and 4 being max-
imal light diffraction (71). Iridal hyper-
emia, a measure of iridal blood vessel
dilation in the iris-ciliary body in addition
to aqueous flare, is also graded (0-4). These
more subjective observations are quanti-
tated at the termination ofthe experiment
by measuring aqueous protein levels and
counting the number ofaqueous inflamma-
tory cells (9,10). The eyes are removed and
processed for histologic/molecular analyses.
Hematoxylin and eosin-stained sections of
eye, removed 18 to 24 hr after endotoxin
injection, show a predominantly polymor-
phonuclear infiltrate with some mono-
nuclear cells and a proteinaceous exudate in
the anterior chamber. Animals are used in
accordance with the Association for
Research in Vision and Ophthalmology
Resolution on the Use of Animals in
Research and approved by the North
Carolina State University Institutional
Animal Care and Use Committee.
In an attempt to dissect the importance
and contribution of the different NOS
isoforms in uveitis, the authors used the
iNOS and cNOS (L-NAME; 100 mM
and 10 mM) and iNOS (AG; 114 mM)
inhibitors in EIU in rabbits (65). These
and additional published studies underscore
the importance ofdetermining which NOS
isoform(s) is important at various stages of
the inflammatory process. Rabbits were
intravitreally injected in one eye with
endotoxin (10 ng) with and without
inhibitor and with endotoxin-free saline
(vehicle) in the contralateral eye. Uveitis
in rabbits coinjected with endotoxin and
L-NAME was almost completely abolished
in a dose-dependent manner, whereas co-
injection of endotoxin and D-NAME,
NG-nitro~D-arginine methylester, the inac-
tive enantiomer, did not suppress uveitis.
Co-injection ofendotoxin andAG, a more
selective inhibitor of iNOS, significantly
suppressed all parameters ofEIU and sug-
gested the importance ofiNOS in ocular
inflammation. To determine if NOS
inhibitors have an effect on established
uveitis, L-NAME was injected 0.5 hr and
6 hr after endotoxin administration. L-
NAME still inhibited uveitis when
injected 0.5 hr after endotoxin. However,
injection ofL-NAME 6 hr after endotoxin
actually exacerbated the inflammatory
response. In contrast, injection ofAG 6 hr
after LPS did inhibit cellular infiltration
and protein extravasation. Thus, the dif-
ferential effects of NOS inhibitors with
different specificities underscore the
importance of the time of their adminis-
tration in ameliorating ocular inflamma-
tion, and could have significant impact on
our understanding ofuveitis and possible
therapeutic intervention.
Because 02,- which reacts with NO to
form ONOO-, also plays a role in intraocu-
lar inflammation (72), we examined aque-
ous humor proteins for evidence of
ONOO- formation by examining protein
nitration using immunoblot analysis (47).
Several immunoreactive bands were
observed in the EIU aqueous humors, com-
pared to a decreased number ofbands of
immunoreactivity in vehicle-injected aque-
ous humors. The immunoreactivity was
eliminated by co-incubation ofantibody
with 10 mM nitrotyrosine. In addition,
aqueous humors from eyes co-injected with
inhibitors ofNOS contained decreased lev-
els of immunoreactivity. Sections of iris-
ciliary processes from inflamed eyes stained
with antinitrotyrosine antibody showed
positive staining, primarily in the cellular
infiltrate. Taken together, these results
suggest that ONOO- may also be involved
in uveitis. Thus, by inhibiting the forma-
tion of NO, formation of the tissue-
damaging ONOO- would also be reduced,
and intraocular inflammation is attenuated.
Additional studies to assess the potential
direct inflammatory effects of ONOO- in
the eye were performed (73). Rabbits were
injected intravitreally every 3 hr for 15 hr
with 3-morpholinosydnonimine hydro-
chloride (SIN-1) (5 mM), which donates
'NO and 02 - simultaneously and
therefore ONOO- or SIN-1 + SOD (10
mM); contralateral eyes received the same
volume and number ofinjections ofvehi-
cle. Coinjection ofan excess ofthe 02--
scavenger SOD with SIN-1 results in only
NO formation and allows intravitreal
effects of NO and ONOO- to be inde-
pendently evaluated. Eighteen hours after
injection, rabbits injected with SIN-1
developed moderate iridal vasodilation
and disruption of the blood-aqueous
barrier, with some cellular infiltration into
the aqueous humor. SIN-1 + SOD- and
vehicle-injected rabbits did not exhibit
significant responses. These results sug-
gest a direct role for ONOO- in uveitis.
Characterization ofthese important uveitic
mediators in the ocular inflammatory
response will provide information critical
to understanding the pathogenesis of
intraocular inflammation.
Conclusions
Administration of NOS inhibitors with
different isoform specificities at the onset
or during EIU exerts differential effects
on this inflammatory response, indicating
that NO is an important mediator of
uveitis. We have demonstrated evidence
of ONOO- formation in uveitic ocular
fluids, and that ONOO- exhibits direct
inflammatory effects in the eye. The
studies described above underscore the
importance of NO and ONOO- in ocu-
lar physiology and pathophysiology.
Development ofeven more selective NOS
inhibitors will be necessary in order to
distinguish the involvement of the differ-
ent NOS isoforms, thus allowing for con-
trol ofharmful, induced NO production,
while not affecting the physiologic actions
ofconstitutive NO release.
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